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Abstract

Eric Goodspeed and Jeannine Durdik

Immunological memory, acquired either by previous
infection or vaccination, affords vertebrates a large margin of
survival. Subsequent exposure to a "remembered" pathogen
signals memory cells to undergo a rapid, clonal proliferation
into armed effector cells. This rapidly mobilized clone mediates
the specific clearance of the trespassing pathogen. Typically,
this secondary recall response effectively dispatches the particular
pathogen prior to any manifest disease pathology. This is the
age-old, enjoyed benefit ofimmunity. Though this appreciation
for immunological memory has been in documentation for
nearly 3 millennia, our ability to intentionally increase its
normal/eve/ offormation is only now beginning. The Durdik lab
and collaborators previously demonstrated that the presence of
pentoxify/line (PF), a clinically administered phosphodiesterase
inhibitor, during priming, produces a decrease in the primary
response and a substantially increased memory response within
the CD4 helper T-ee// contingent. Here it is shown that the
presenceofPF during priming results in enhanced CDS cytotoxic
secondary responses. CDS T-cel/s respond by directly killing
cells hosting intracellular infections. A significantly enhanced
cytotoxic memory response was demonstrated both 60 and 90
days post-priming to a specific peptide antigen called HY (amino
acid sequence: KCSRNRQ YL) under a PF-cover during priming,
in contrast to groups without PF administration. These findings
suggest a substantial potentia/for the development ofenhanced
vaccines for intracellular pathogens.

Introduction
When the immune system of a vertebrate encounters a new
antigenic threat, it responds by entering two mutually exclusive
pathways to produce separate populations of dispatching cells,
known as armed effector cells (Wong, 1996) and memory cells
(Zinkemagel, 1996). The larger pool of short-lived armed
effector cells are responsible for directly clearing the immediate
pathogenic threat. The distinct population oflong-lived memory
cells insure that subsequent threats from the same pathogen will
be recognized and cleared with greater expediency (Zinkemagel,
1996). A pharmacological method to intentionally modulate this
differentiation pathway to generate more memory cells would be
ideal within the scheme of vaccination.
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The Durdik lab and collaborators previously demonstrated
that the presence ofthe phosphodiesterase inhibitor, pentoxifylline
(PF), during priming modulates the differentiation pathway of
CD4 helper T-cells to favor a larger commitment of memory
cells at the expense of armed effector cell proliferation (Gupta,
1999). The hypothesis followed that the presence of PF during
priming would shift the immune cell differentiation pathway
such that the immunological memory CDS killer T -cell response
wouldbesignificantlyenhancedascomparedtonormal,untreated
levels. The following experimental design provided conclusive
data that a CDS T -cell memory response, both 60 and 90 days
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post-priming, can be enhanced with the presence of PF during
priming.

Experimental design-Materials and methods
Pentoxifylline
Pentoxifylline (PF), a phosphodiesterase inhibitor, is a
clinical agent commonly administered as an anti-inflammatory
and blood thinner (McEvoy, 199S). It has been demonstrated
that the phosphodiesterase inhibitory function of PF increases
intracellular levels of the ubiquitous, secondary messenger,
cyclic adenosine monophosphate (cAMP) (McEvoy, 199S).
Antigenic system
Memory CDS T-cells were generated within an in vivo
mouse, HY -antigen system. The genetic variance between
genders of the syngeneic inbred C57BUJ6 mouse strain (Jackson
Laboratory, 19S9), namely, the male possession of the HYantigen encoding Y-chromosome (Scott, 1995), provided the
immunogenic basis for the system. Each experimental timepoint, day 60 and day 90, consistedof2-3 eight-week-old female
C57BUJ6micethatreceived,ondayO,apriminginjectionofl07
male C57/BUJ6 splenocytes. In some experiments, 107
B6.THY 1.1 male splenocytes were employed as primers. These
splenocytes possess two immunogenic differences (HY and
THYl.l) relative to the female C57BUJ6 mice. This was
performed to increase the overall helper CD4 immune response
and subsequent recall cytotoxic CDS activity. Half of the mice
received PF injections (1.5 mg/mouse) once a day from day -1 to
day4. FemaleC57BUJ6micethatdidnotreceivePForpriming
injections were employed as controls.

In vitro effector:stimulator cultures
At the experimental time-points, day 60 and day 90,
splenocytes from each group were harvested and cultured with
male C57BUJ6 stimulator-splenocytes ina single cell suspension
at a ratio of 5: 1 ( 107 effectors:2X1 ()6 stimulators). These cultures
were incubated at 37oo C in 5% CO, for 6 days to allow the
priming-generated. HY-specific, niemory CDS T -cells to
proliferate into armed, HY-specific effector cells. Control
effectors, generated from female mice neither receiving priming
nor PF, were identically cultured.
Synthesis ofHY and LCMV-peptide
With the assistance of Dr. Koeppe's biochemical research
lab, the previously identified HY-peptide (amino acid sequence:
KCSRNRQYL)(Markiewiecz, 1998)andLCMV-peptide(amino
acid sequence: KAYVNFATM) (Kyburz.1993)were synthesized
using the solid phase peptide synthesis (SPPS) technique
(Merrifield, 1997). These synthetic peptides were designed to fit
within the particular sequence motif of the mouse class I major
histocompatibility complex (MHC I), D gene locus, b allele (H2.I)b) surface expressed molecule (Markiewiecz, 1998). The
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LCMV-peptide was employed as an H-2Db-binding control
peptide such that it would bind into the MHC I but not become
a recognizable target for the HY -specific effector cells. Each
peptide was analyzed for purity by ultraviolet spectroscopy and
High Performance Liquid Chromatography.
RMA-S T -cell lymphoma line
The female, immortal T-cell line, known as RMA-S
(Ljunggren, 19S5), was employed as target cells to test for the
cytotoxic killing ability of the previously in vitro generated ~y
specific effector cells. The RMA-S cell is incapable ofexpressmg
a stable MHC I due to a mutation in the Transporter associated
with Antigen Presentation (TAP) gene locus (Kaer, 1992).
However, if RMA-S cells are incubated with peptide known to
bind within its MHC I (H-2Db), a stabile surfaced expressed
MHC !:peptide complex is formed (Townsend, 1996). It is this
critical complex that triggers the peptide-specific CDS T -cell to
unleash its arsenal of cytotoxic chemicals upon the target cell.
Thus, RMA-S cells were incubated with the previously
synthesized HY and LCMV peptides for 16 hours prior to 51 Cr
labeling (see below) to create target cells. This technique is
known as peptide loading. RMA-S cells without peptide loading
are deficient in MHC class I. These become targets for Natural
Killer cells and are therefore not an appropriate target population
to serve as a control.
Male Targets
Male C57BUJ6 splenocytes were employed as alternative
HY-antigenic target cells.
Chromium-51 cytotoxic release assay
The various RMA-S target cells were incubated with 100
_Ciofradiolabeleddisodiumchromate(N~51 Cr0). Thegamma

energy emitting chromium-51 (5 1Cr) radionuclide is readily
incorporated into the target cell cytosol via calcium ion channels
(Coligan, 1996). Spontaneous release and reuptake is relatively
low due to irreversible binding of 51 Cr with cytosolic protein
(Coligan, 1996). After one hour of incubation (at 3 7oo C and 5%
CO,) the targets were washed three times. Effector cells were
collected from their6 day cultures and cell recoveries determined.
Within a 96-well V-bottom microtiter plate effector-to-target
ratios of 50:1, 25:1 and 12: 1 were created in replicate with target
cells constant at a quantity of 10"'. The assays were designed with
nine to twelve effector:target combinations involving an
intersecting grid of the three effector treatment groups and the
three to four targets types in a total volume of200_l. Spontaneous
51
Cr release values were established with wells only containing
target cells and complete media. The assay plate was centrifuged
and incubated for six hours at 37oo C and5% CO,. This provided
the proper physiological condition for CDS- cell-mediated,
cytotoxic lysis of the 51 Cr-labeled target cells (Rodrigues, 1992),
and the subsequent release of their cytosolic5 1Cr into the
surrounding media. After incubation the assay plate was
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centrifuged and 150_1 of supernatant of each well was collected
for gamma activity detection in a fully automated Packard
Cobra® gamma counter. To establish a total, potential gamma
count, 75_1 of each type of 51 Cr labeled target cell stock was
directly counted. Cytotoxic activity was correlated with gamma
counts per minute (CPM) by the following equation:
(Experimental CPM value-Spontaneous ReleaseCPM
value) I (Total CPM value- Spontaneous Release
CPM value) x 100 =%specific lysis
Final cytotoxic activity, or percentage specific lysis, is a
measure of the in vivo generated memory CDS T -cell contingent.

Results
Figure 1a provides data from the three treatment groups
against HY-peptide loaded RMA-S target cells at a 50: 1 E:T ratio
60 days post-priming in an HY-antigen system. The control
effector cell group generated an expected low baseline specific
lysis of S%. The untreated effector group (hatched bar) did not
show any significant increase of specific lysis relative to the
control group. The PF-treated effector cell group did show a
significant (p=.042) increase of specifc lysis relative to the
untreated group. Figure 1b provides data from the three treatment
effector cell groups against male splenocytes at a 50: 1 E:T ratio
60 days post-priming in an HY-antigen system. The untreated
control effector cell group (checkered bar) elicited an expected
low basline specifc lysis of nearly 0%. The untreated effector
cell group (hatched bar) did not show any significant increase of
specific lysis relative to the control group. The PF-treated
effector cell group (solid bar) did show a significant (p=.037)
increase of specific lysis relative to the untreated group.
Figure 2a provides data from the three treatment groups
against the irrelevant control LCMV-peptide loaded RMA-S
target cells at a 50:1 E:T ratio 90 days post-priming in an HYantigen system. All treatment groups elicited specific lysis
values consistent with a non-specific target. Figure 2b provides
data from the three treatment effector cell groups against HYpeptide loaded RMA-S cells at a 50:1 E:T ratio 90 days postpriming in an HY-antigen system. The untreated control effector
cell group (checkered bar) elicited an expected low basline
specifc lysis of 8%. The untreated effector cell group (hatched
bar) did not show any significant increase of specific lysis
relative to the control group. However, the PF-treated effector
cell group (solid bar) did show a large significant (p=.019)
increase of specific lysis relative to the untreated group.
Figure 3a provides data from the three treatment groups
against the irrelevant control LCMV-peptide loaded IU.IA-S
target cells at a titrated E:T ratio from 50:1 to 12:1 60 days postpriming in an THY 1.1-antigen system. All treatment gro~ps
elicited specific lysis values consistent with a non-specific
target. Figure 3b provides data from the three treatment e~ector
cell groups against HY-peptide loaded RMA -S cells at a titrated

Published by ScholarWorks@UARK, 2000

45

E:T ratio from 50:1 to 12:1 60 days post-priming in an HYantigen system. The untreated control effector cell group
(checkered bar) elicited an expected basline specifc lysis of S%
and followed the titration trend. For the first time. the untreated
effector cell group elicited a significant specific lysis relative to
the control group along the titration curve. This data can be
explained by more initial CD4 helper T-cell generated IL-2
during priming due to the additional THYl.l antigen. The PFtreated effector cell group demonstrated the largest significant
increase (p<.005) of specific lysis. following the titration curve.
relative to the untreated group.
Most recently our lab designed and performed an experiment
to determine if the observed enhanced memory cytotoxicity was
a direct result of an increased memory CDS T -cell contingent and
not exclusively a matter of help from CD4 memory helper Tcells. Though several crucial steps were altered to bypass any
potential CD4 T-cell help at the priming event, the general
protocols of the previously described experiments were followed.
Mice were primed with syngeneic female C57BU6J splenocytes
loaded with the MHC !-specific LCMV-peptide to insure an
exclusive CDS T -cell recognition of the MHC I:LCMV-peptide
complexes. This procedure provided two experimentally relevant
functions: LCMV peptide cannot stimulate a CD4 T -cell response
and does not bind to the MHC II; and this CD4 bypass insured
that any observed recall cytotoxicity was a direct result of a
memory CDS T -cell contingent.
107 Female splenocytes were loaded with 200_g ofLCMVpeptide in a total volume of 1 rni of serum-free media and
incubated for one hour at 37oo C and 5% C02" The serum-free
media allowed the endogenous peptide of the splenocytes to
briefly dissociate with their MHC I molecules. The
__microglobulin sub-unit of all MHC I is in a non-covalently
bound/unbound state of equilibrium (Rock, 1991 ). Dissociation
of the __microglobulin sub-unit destabilizes the MHC I which
leads to loss of its bound peptide. At this juncture, the
thermodynamically advantaged (law of mass action) synthetic
peptide usurps the original endogenous peptide position. Fetal
calf serum typically employed to make cell culture media
"complete" contains large quantities of ___microglobulin subunits that have been shown to bind to mouse MHC I (Rock,
1991 ). In terms of attempting to load splenocytes with exogenous
peptide, this pushes the bound/unbound equilibrium to the
unfavorable bound state. Thus, a serum-free medium is crucial
to peptide loading. Each mouse was primed v.ith 107 LCMVpeptide loaded cells and treatment-group mice received injections
of PF at 1.5 mg per day per mouse on day -1 to day 4, relative
to priming. On day 30, post-priming, spleens were harvested and
cultured at the 5:1 E:T ratio with LC.MV -peptide loaded female
splenocytes. In vitro generated LCMV-specific effector cells
were mixed separately with 51 Cr-labeled IU.1A-S cells loaded
with LCMV-peptide or the irrelevant HY-peptide at an E:T ratio
of25:1.
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Figure 4 demonstrates that PF-treated effectors exhibited a
greater LCMV -specific lysis than the non-treated effectors. This
lends support to the claim that the previously observed enhanced
CDS recall cytotoxicity is a direct result of an increased CDS Tcell contingent. Though this particular experiment requires
confirmation by repetition, these data offer a positive trend to the
expectation of a PF-mediated memory CDS T-cell pool.
In toto, these experiments designed with multiple control
and experimental conditions provided statistically significant
evidence to the proposed hypothesis that the presence of PF
during priming enhances CDS T-cell immunological memory.

Discussion
The potency of the vaccine, as the premiere method of
disease prevention and control, is founded on the ability to
intentionally induce the generation oflong-lived, antigen-specific
memory cells (Christensen, 1994). Though the vaccine is a
fruitful discovery, it must be understood that it falls short of its
potential. Within the vaccine-induced immune response the
natural production of antigen-specific effector cells is without
justification, for, ultimately, the stimulating agent is nonpathogenic, only immunogenic. To advance the vaccine within
the scope of its ideal, we must be able to shift the fulcrum of this
balanced cell differentiation pathway to favor an exclusive and
robust production within the memory cell contingent. PF has
previously (Gupta, 1999) demonstrated the ability to diminish
the CD4 T -cell primary response while enhancing CD4 memory.
This work shows that PF enhances CDS T-cell recall activity.
These experiments offer a tantalizing potential to expand the
reach of our preventative intentions.
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Faculty Comments:
Mr.Goodspeed'sfacultymentor,Dr.JeannineM.Durdik,
made the following comments about his project:
This letter is to explain the value and pertinence of the
work of Eric Goodspeed, an undergraduate researcher
in my lab, who has made a very important and
independent contribution.

For successful protection against various infections,
the development of an adoptive immune response is
necessary. When the same infection is encountered
again by the individual, the immune response
specifically directed against target molecules of the
infectious organism is significantly different from
that seen during the first encounter in being much
larger. This ability of the immune system to
"remember" past history and respond better to
reinfection is called immune memory.
However, in response to an infection, cells of the
immune systemmustnot only generate this quiescent
state called immune memory, but must also mount a
response that is immediately effective and useful in
combating the ongoing infection. This pathway of
immune cell differentiation must thus lead to the
development of effector cells. Since effector cells are
to be used immediately, a major difference between
memory and effector cells is that memory cells must
be capable of undergoing proliferation upon antigen
re-exposure, while effector cells must be capable of
immediate function without proliferating. The
immune system, in response to a natural infection,
must therefore strike a balance between the generation
of memory and effector cells.
However, the requirements are significantly different
during vaccination. Vaccination, as commonly
understood, is a mock infection, in that it exposes the
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body to the molecular targets of a given infectious
agent without actually causing disease. Thus, there is
no immediate need for effector immune responses to
vaccination.

application of this agent (pentoxifylline), or some
derivative of it, into a vaccine might be an effective
approach to eliciting stronger immune responses by
the individuals who receive the \'accines.

The pathways that strike a balance between effector
and memory commitment are mutually exclusive, so
that stimulating the immune system too hard may
lead to the generation of short-lived effector immune
cells to the detriment of the generation of longlived
memory immune cells. A dilemma is thus apparent;
overstimulating the immune system by a vaccine may
be detrimental to the generation of immune memory
against it, but understimulation may also result in
poor generation of both effector and memory
responses. The solution to this difficulty is the
identification and use of immune response mod)fiers
that affect the biochemical pathways governing
effector versus memory generation differentially. Such
modulators should suppress effector generation and
skew tne balance in favor of memory generation.
What Eric has done is describe such an
immunomodulatory intervention and how it relates
to memory generation for one branch of the immune
response, killer T cells. He has discovered that by
administering the drug pentoxifylline during
immunization that he can demonstrate the persistence
of immune memory 100 days later. Without this
treatment, there is practically no detectable T cell
killing. This finding will have a significant impact on
the field of immunology.

Dr. Douglas Rhoads, Associate Professor and Vice-chair
of the Department of Biological Sciences, had this to say about
Mr. Goodspeed:

Dr. Dwight E. F. Talhurt,ProfessorandVice-Chairofthe
Department of Biological Sciences said of Mr. Goodspeed's
work:
I feel that Eric is both and outstanding individual as
well as a student. I have known him for about 3 years
while he has been a student major in the Department
of Biological Sciences. Also, he was a student in my
senior I graduate level course in Microbial Physiology
where he demonstrated clearly his ability to assimilate
and gain understanding of a large body of technical
informationconcerningthe biochemistry and genetics
which underlie microbial growth. In this class he was
in the top 5% of about 60 advanced students. Overall,
hisGPAisabout3.6.Inadditiontohisstrongclassroom
and laboratory abilities, Mr. Goodspeed has been
active in various honorary and community service
endeavors.

Mr. Goodspeed's work, which he seeks to publish in
Inquiry, is an outgrowth of work which he began with
a "SILO Undergraduate Research Fellowship" under
the very able direction of his mentor and research
advisor, Dr. Jeannine Durdik. The work is entitled
"PentoxifyllinemodulationofthecytotoxicCD8 T-Cell
differentiation pathway to enhance the memory cell
contingent"-which means that he an his advisor
have possibly discovered a way to enhance immune
responses to disease causing agents. If so, the
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I have been asked to provide a letter of support
regarding the submission by Mr. Eric Goodspeed of
an abstract and project for a research award and for
publication in the new U of A undergraduate journal,
Inquiry. I can think of no student that is more
appropriate or more deserving of such an award. I
had Eric in Cell Biology Lecture and Lab. Eric clearly
distinguished himself in this course as one of the
brightest and most dedicated and attentive students
in the class of 90 students. This is an intensive course
incellmetabolismandstructure. Theexamsallrequire
lengthy, hand written answers to questions based on
the readings and lectures. Eric sat near the front,
attendedallbutonelectureandaskedsomeofthebest
questions. The only period he missed he came to me
and apologized for missing. He scored extremely well
onalltheexamsandhadoneofthehighestcumulative
scores in the class. For that reason I kept in contact
with Eric and advised him about getting involved in
a research project for his senior thesis requirement.
Unfortunately, he selected to work in Dr. Jeannine
Durdik'slab. That is unfortunate forme because I was
hoping he would choose my lab. It is fortunate for him
and for Dr. Durdik that he chose her lab. I am well
aware of Dr. Durdik's research program as I have
been on several thesis committees for her graduate
and Undergraduate students. Dr. Durdik molds
thinkers and researchers trained in immunology and
molecular biology. The students receive a well
rounded education and training that is competitive
with the best University settings: I think Eric has been
very successful in his undergraduate project. I have
witnessed him on weekdays, weekends and evenings
working in the lab. He enjoys the work and appears
quite dedicated to his science. I will add that his
personality and attitude make him pleasant to
converse with and open to suggestion and discussion.
I have read the abstract to his proposal and am excited
about the possibility that Dr. Durdik and Eric will be
extending the work on pentoxifylline to CDS+ cells.
As this effort has the potential to develop new
patent-able drugs for human health I find it well
worth pursuing. I give Eric Goodspeed my highest
rating, I think he is in the top 1-5% of all our students
in Biological Sciences (class of 600). I highly
recommend that you publish his findings and award
him for this effort.
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Figure 1. PF-mediated enhancement of CDS T-cell memory in vivo 60 days post-priming. Female C57BL/ 6J mice primed with 1()1
C57BL/6J splenocytes were treated either with PBS or l.SmgPF per mouse per day from day-one to day-four of priming. Splenocytes
at day-sixty post-priming from unprimed (checkered bar), primed+PBS-treated (hatched bar) or primed+PF-treated (solid bar) were
stimulatedinvitroforsixdayswithmalesplenocytesandusedaseffectorcellsata50:1effector:targetratiotolyse(a) 51 Cr-labeledRMAS target cells incubated with HY-peptide or (b) 51Cr-labeled male splenocyte targets in a six-hour cytotoxic assay to determine
percentage of cytotoxicity.
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Figure 2. PF-mediated enhancement of CDS T-cell memory in vivo 90 days post-priming. Female C57BL/ 6J mice primed with 10
male C57BL/ 6J splenocytes were treated either with PBS or 1.5 mg PF per mouse per day from day -1 to day 4 of priming. Splenocytes
at day 60 post-priming from unprimed (checkered bar), primed+PB5-treated (hatched bar) or primed+PF-treated (solid bar) were
51
stimulated in vitro for 6 days with male splenocytes and used as effector cells at a 50:1 effector:target ratio to lyse (a) Cr-labeled 1Uv1A51
S target cells loaded with the irrelevant LCMV-peptide or (b) Cr-labeled HY-peptide loaded IUvfA-5 targets in a 6-hour cytotoxic assay
to determine percentage of cytotoxicity.
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Figure 3. PF-mediated enhancement of CDS T -cell in vivo 60 days post-priming. Female C57BL/6J mice primed with 10" male THYl.l splenocytes
were treated either with PBS of 1.5mg PF per mouse per day from day-one to day-four of priming. Splenocytes at day 60 post-priming from unprimed
(square), primed+ PBS-treated (triangle) of primed+PF-treated (diamond) were stimulated in vitro for six days with male splenocytes and used as effector
cells at effector:target rations of 50:1, 25:1 (and 12:1 in B) to lyse (A) 51Cr-baleled RMA-5 target cells loaded with the irrelevant LCMV-peptide of (B) 51Crlabeled RMA-5 targets loaded with the HY-peptide in a six-hour cytotoxic assay to determine percentage of cytotoxicity.
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Figure 4. Generation of an MHC class I restricted CDS T-cell response by priming with LCMV-peptide loaded cells. Female C57BL/
6J mice were primed with LCMV-peptide loaded syngeneic female splenocytes. Restimulated LCMV-specific effectors were developed 30 days postpriming and mixed with 51 Cr-labeled, LCMV-peptide loaded RMA-5 cells at an effector: target ratio of 25:1 (2.5x10S:lx1Ql ). LCMV-primed, PFtreated mice-generated effectors (solid bar) show a greater cytotoxic activity against the LCMV-peptide loaded RMA-5 target cell than the untreated
LCMV-specific effectors (hatched bar).
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